Skip to main content
. 2015 May 27;2015:672653. doi: 10.1155/2015/672653

Table 1.

Characteristics of the study population (n = 68) at the start of the supplementation period.

Variable Mean or median Standard deviation or interquartile range
Age (years)a 65.7 7.0
25(OH)D3 (nmol/L)b 57.0 11.0
HbA1c (mmol/mol)b 40 3
HbA1c (%)b 5.8 2.5
Fasting glucose (nmol/L)a 6.1 0.7
120 min glucose (nmol/L)a 6.1 2.5
Fasting insulin (mU/L)b 12.0 6.0
120 min insulin (mU/L)c 61.9 62.3
HOMA2 %betab 82.2 24.1
HOMA2 %ISa 70.2 39.2
HOMA2 %IRb 1.6 0.8
Waist circumference (cm)b 106 9
Body mass index (kg/m2)b 29.4 2.7
Systolic BP (mmHg)a 144 30
Diastolic BP (mmHg)b 92 10
Serum PTH (pg/ml)a 42.6 12.7
Serum calcium (mM)b 2.33 0.07
Serum creatinine (µmol/L)a 71.7 14.5
Serum ALAT (U/L)a 27.5 17.6
Serum GGT (U/L)a 29.4 23.7
Serum TSH (mU/L)a 2.6 1.7
Serum HDL cholesterol (mmol/L)b 1.4 0.4
Serum LDL cholesterol (mmol/L)b 3.2 0.9
Serum triglycerides (mmol/L)a 1.3 0.7
Serum ApoA1 (g/L)b,c 1.6 0.2
Serum ApoB (g/L)b,d 1.0 0.2
Serum adiponectin (µg/mL)a,c 4.8 3.3
Serum C-reactive protein (mg/L)a,c 1.2 1.5
Plasma TNF receptor II (pg/mL)a 2240 480
Plasma IL-6 (pg/mL)a 1.3 0.8
Plasma IL-1 beta (pg/mL)a 0 0
Plasma IL-1 receptor antagonist (pg/mL)a 200 95

aMedian and interquartile range; bmean and standard deviation;c n = 66; d n = 65.

25(OH)D3: 25-hydroxyvitamin D3; ALAT: alanine aminotransferase; Apo: apoprotein; GGT: gamma-glutamyl transferase; HDL: high-density lipoprotein; HOMA: homeostatic modeling assessment; IL: interleukin; IR: insulin resistance; IS: insulin sensitivity; LDL: low-density lipoprotein; PTH: parathyroid hormone; TNF: tumor necrosis factor; TSH: thyroid-stimulating hormone.

HHS Vulnerability Disclosure